(TPST) Tempest Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
See the Bigger Picture
This Tempest Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual report content, not just a description. Buy the full version to get the complete ready-to-use analysis.
Stars
No approved products
Tempest Therapeutics had no approved oncology products by end-2025, so it had no commercial market share base to fit a BCG Star. Its value still depended on clinical readouts and pipeline execution, not on product sales. As of 2025, the company remained pre-revenue and tied to trial outcomes rather than a growing marketed franchise.
TPST-1495 lead asset
TPST-1495 is Tempest Therapeutics, Inc.'s lead small-molecule program, so it sits closest to a Star if the data improve. It blocks EP2 and EP4, two prostaglandin E2 receptors tied to tumor immune evasion. If upcoming clinical readouts show better response and safety, TPST-1495 could shift from a pipeline bet to the company’s main growth driver.
TPST-1120 second clinical asset
TPST-1120 is Tempest Therapeutics, Inc.’s second clinical asset and a Stars-style bet in the BCG matrix. It is a PPAR alpha blocker that reached Phase 1 testing in solid tumors, giving Company Name a second differentiated oncology shot. This mattered in a small pipeline: one more clinical asset can still change the growth path.
Solid tumor oncology focus
Tempest Therapeutics, Inc. targets solid tumors, which make up about 90% of adult cancers and a global market with 20.0 million new cases in 2022, projected to reach 35.0 million by 2050. That scale keeps the science active and raises the payoff for any winning asset, so this is a strong Stars-style platform if it can keep hitting clinical milestones.
- Large, durable oncology demand
- High value if trials succeed
TREX1 immune-response biology
TREX1 is a preclinical immuno-oncology bet tied to innate immune control in cancer, so it fits a high-growth field where many FDA-approved checkpoint drugs now anchor care. Tempest Therapeutics, Inc. has no product revenue, so any TREX1 win would matter as pipeline value, not current sales. Positive biology data could move it from discovery to a more credible asset.
- TREX1 links to cancer immunity
- No product revenue today
- Validation could lift pipeline value
Tempest’s Growth Story Is All Pipeline, No Revenue Yet
Stars in Tempest Therapeutics, Inc. are still pipeline assets, not revenue drivers. TPST-1495 and TPST-1120 are the clearest growth bets, but as of 2025 Tempest Therapeutics, Inc. had no approved oncology product and no commercial sales. The upside is tied to execution in a cancer market with 20.0 million new cases in 2022 and a forecast 35.0 million by 2050.
| Asset | Stage | Star signal | Key risk |
|---|---|---|---|
| TPST-1495 | Clinical | Main growth driver | Readout risk |
| TPST-1120 | Phase 1 | Second shot | Early data risk |
| TREX1 | Preclinical | Future upside | Validation risk |
What is included in the product
Detailed Word Document
Tempest Therapeutics’ BCG Matrix spots pipeline assets by growth and share, highlighting invest, hold, and divest priorities.
Editable Excel File
One-page BCG Matrix for Tempest Therapeutics, Inc., quickly clarifying portfolio priorities and easing strategic decisions.
Reference Sources
Provides a credible source trail for Tempest Therapeutics, Inc., helping decision-makers verify key claims fast and trust the analysis.
Cash Cows
No approved products
Tempest Therapeutics had no approved or marketed products at end-2025, so it had no commercial sales to create the steady cash flow a Cash Cow needs. It stayed dependent on external funding and clinical readouts, with FY2025 still showing research-stage economics rather than product revenue. In short, there was no cash-generating asset to classify here.
No mature revenue stream
Tempest Therapeutics, Inc. was still in clinical development, with no approved products and no mature, low-growth revenue stream to classify as a Cash Cow. That meant operating cash generation was minimal or absent, and the business stayed dependent on external funding, not product sales. In BCG terms, this is not a cash engine; it is a pipeline-stage biotech with ongoing R&D burn.
No established market share
Cash Cows need high share in a mature market, but Tempest Therapeutics, Inc. had no approved oncology drug and no commercial market share. As a pre-commercial biotech, it reported no product revenue, so its assets were still in development, not in a cash-generating stage. That makes the "Cash Cows" label a poor fit for FY2025 and FY2026.
No royalty portfolio
Tempest Therapeutics, Inc. had no royalty portfolio and no product sales, so there was no recurring cash engine to offset R&D burn. With 0 royalty revenue and 0 commercial products in the latest filings, cash inflows depended on equity or debt funding, not a cash cow.
- No royalty income
- No product-level cash cow
- Funding relied on capital raises
No legacy franchise
Tempest Therapeutics, Inc., founded in 2011, was still a development-stage biotech, so it had no legacy franchise to harvest as cash cows. Its portfolio was being built through R and D, and it had no product revenue to fund growth from an older mature brand. That means cash generation depended on financing, not harvest.
- No mature revenue base
- R and D drove value creation
- Cash came from capital raises
Tempest Therapeutics: No Cash Cow, Just a Pipeline Biotech
Tempest Therapeutics, Inc. had no approved products in FY2025, so it had no Cash Cow asset. Revenue from products was 0, and cash use still came from R and D, not operations. In BCG terms, this is a pipeline biotech, not a mature cash engine.
| FY2025 metric | Value |
|---|---|
| Product revenue | 0 |
| Approved products | 0 |
| Cash Cow fit | No |
What You See Is What You Get
Tempest Therapeutics, Inc. Reference Sources
The Tempest Therapeutics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the full, professionally formatted report ready for immediate use. Once purchased, you’ll get the same file for downloading, reviewing, or sharing with your team.
Dogs
No commercial dogs
Tempest Therapeutics had no marketed brands or product sales at end-2025, so there were no commercial Dogs to classify. Dogs are low-share products in low-growth markets, and that did not fit a pre-commercial company with zero revenue from approved products in 2025. Instead, Tempest was still funding clinical development, not carrying legacy assets that dragged on cash flow.
No low-growth product line
Tempest Therapeutics, Inc. had 0 legacy commercial products, so this was not a "Dogs" case of propping up a slow-growth line. Its 2025 pipeline stayed centered on early-stage oncology assets, which are high-risk and still far from stable sales. With no mature therapy generating steady revenue, the BCG Matrix fit is better as question marks, not dogs.
No divested brand disclosed
Tempest Therapeutics, Inc. did not disclose any divested brand or abandoned commercial product in its latest profile, so there is no clear end-2025 dog asset on a product basis. The pipeline stayed narrow, centered on clinical-stage oncology assets rather than a broad commercial franchise. That limits the case for a legacy low-growth, low-share dog.
No obsolete manufacturing franchise
Tempest Therapeutics, Inc. is a clinical-stage small-molecule developer, so it does not run a large commercial manufacturing base. There is no disclosed legacy factory business or declining product line that would fit a classic Dog in the BCG Matrix. In 2025, the Company’s profile still centers on pipeline development, not scaled production or mature-unit monetization.
- No obsolete manufacturing franchise
- No legacy plant-based cash cow decline
- Dog risk is product, not operations
No cash-trap product
Tempest Therapeutics fits the "no cash-trap product" view: it had no mature commercial drug to drain capital, and its spending stayed centered on clinical development, which is normal for a biotech. In 2025, the company was still in the pre-commercial stage, so no product was tying up cash in a low-return market.
- Clinical spend, not legacy product drag
- No commercial revenue stream to support
- Biotech losses were development-led
So, as a BCG Dogs case, the issue was not a bad product cash trap; it was the cost of advancing pipeline assets before any sales existed.
Tempest Therapeutics Had No Dogs in 2025—Purely Pipeline-Led
Tempest Therapeutics, Inc. had no marketed products, no product sales, and no legacy brand drag in end-2025, so there was no real Dogs bucket to classify. Its BCG profile was still pipeline-led, with clinical spend tied to oncology development rather than a low-share, low-growth cash trap.
| 2025 metric | Value |
|---|---|
| Marketed products | 0 |
| Product sales | 0 |
| Dog assets | None disclosed |
Question Marks
TPST-1495 Phase 1
TPST-1495 is Tempest Therapeutics, Inc.'s clearest Question Mark: a Phase 1 dual EP2/EP4 inhibitor tested in initial human studies in solid tumors. EP2/EP4 blockade targets a developing oncology niche, but clinical payoff is still unproven and depends on early safety and response data. In BCG terms, it has high upside, but no clear proof yet to move out of the question-mark box.
TPST-1120 Phase 1
TPST-1120 remained in Phase 1, so Tempest Therapeutics, Inc. still lacked later-stage proof for its PPAR alpha approach in solid tumors. With only early clinical data, the asset has not yet shown the efficacy signals needed to support a larger capital commitment. In BCG terms, it fits a Question Mark: high potential, but still waiting for meaningful human data to justify scale-up.
TREX1 discovery program
TREX1 discovery was a preclinical cancer-target search at Tempest Therapeutics, Inc., so it sat earlier than the company’s clinical assets and carried far higher failure risk. That makes it a classic Question Mark in the BCG Matrix: high uncertainty, but if validated, TREX1 could open a new oncology lane.
Pre-revenue oncology model
Tempest Therapeutics, Inc. stayed a clinical-stage oncology Company at end-2025, so its BCG position is a "Question Mark": high upside, but no sales base. Its current market share was 0 because it had no approved products and no product revenue. Value depended on trial data, not cash flow.
- Clinical-stage only at end-2025
- Product revenue: 0
- Market share: 0
- Upside tied to pipeline readouts
Small-molecule pipeline expansion
Tempest Therapeutics, Inc. is still betting on novel small-molecule oncology assets, and that fits a classic Question Mark: the idea can scale hard if a trial wins, but most early cancer drugs never make it to market. Across oncology, only about 10% of drugs that enter phase I reach approval, so pipeline expansion can add upside, but it also keeps cash burn and clinical risk high.
- High upside, low hit rate
- Pre-commercial, trial-led value
- Success depends on clinical data
If Tempest Therapeutics, Inc. can turn one program into proof of concept, the bucket can move toward Star status; if not, it stays a costly bet on optionality.
Tempest Therapeutics: All Pipeline, No Revenue
Tempest Therapeutics, Inc. fits BCG Question Marks because its pipeline is still pre-revenue and high-risk. TPST-1495 and TPST-1120 were still in Phase 1 at end-2025, while TREX1 was still preclinical. No approved products meant product revenue and market share stayed at 0.
| Asset | Status | BCG fit |
|---|---|---|
| TPST-1495 | Phase 1 | Question Mark |
| TPST-1120 | Phase 1 | Question Mark |
| TREX1 | Preclinical | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.